Spark Therapeutics (NASDAQ: ONCE) announced positive top-line results from the Phase 3 pivotal trial of its lead gene therapy product ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE